Enzymes

Global Biocatalysis & Biocatalyst Market Report: Growth at a CAGR of 15% Predicted from 2019 to 2024 - ResearchAndMarkets.com

Retrieved on: 
星期一, 六月 14, 2021
Health, Biotechnology, Chemistry, Physical sciences, Natural sciences, Catalysis, Organic chemistry, Enzymes, Biocatalysis, Trend, Enzyme

Some of the features of Biocatalysis & Biocatalysts Market 2019-2024: Trends, Forecast, and Opportunity Analysis include:

Key Points: 
  • Some of the features of Biocatalysis & Biocatalysts Market 2019-2024: Trends, Forecast, and Opportunity Analysis include:
    Market size estimates: Biocatalysis & biocatalysts market size estimation in terms of value ($M) shipment.
  • Trend and forecast analysis: Market trend (2013-2018) and forecast (2019-2024) by catalyst type, and end use industry
    Segmentation analysis: Market size by end use industry, catalyst type, and region
    Regional analysis: Biocatalysis & biocatalysts market breakdown by North America, Europe, Asia Pacific, and the Rest of the World
    Growth opportunities: Analysis of growth opportunities in different applications and regions for biocatalysis & biocatalysts in the biocatalysis & biocatalysts market.
  • Q.7 What are some changing demands of customers in the biocatalysis & biocatalysts market?
  • Q.11 What M & A activities have taken place in the last 5 years in this, biocatalysis & biocatalysts market?

2021 Global Tributyl Citrate (CAS 77-94-1) Market Research Report - Key Manufacturers and Distributors - ResearchAndMarkets.com

Retrieved on: 
星期五, 六月 11, 2021
Chemicals, Plastics, Manufacturing, Enzymes, Chemical substances, Citrates, Chelating agents, Food acidity regulators, Citric acid, Citrate (pro-3S)-lyase, Citrate (Re)-synthase

The "Tributyl citrate (CAS 77-94-1) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Tributyl citrate (CAS 77-94-1) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of Tributyl citrate.
  • The Tributyl citrate global market report key points:
    The first chapter introduces the product (composition, structure, hazards, storage, toxicological & ecological information, etc.).
  • The fifth chapter deals with Tributyl citrate market trends and forecast, distinguish Tributyl citrate manufacturers and suppliers.

Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) - 2021 Drugs in Development Report - ResearchAndMarkets.com

Retrieved on: 
星期五, 六月 4, 2021
Health, Pharmaceutical, Enzymes, Lysosomal storage diseases, Maltase, Acid alpha-glucosidase, Alpha-glucosidase, Hydrolases, Carbohydrates, Lysosome, Glucosidases, Glucocerebrosidase, GAA, Glucan 1,4-a-glucosidase

The "Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) - Drugs in Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) - Drugs in Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • According to the recently published report Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) pipeline Target constitutes close to 19 molecules.
  • The report outlays comprehensive information on the Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
  • It also reviews key players involved in Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) targeted therapeutics development with respective active and dormant or discontinued projects.

Akebia Therapeutics Announces Presentations at ERA-EDTA Virtual Congress 2021

Retrieved on: 
星期四, 六月 3, 2021
Chemistry, Enzymes, Acetic acids, Physical sciences, Transcription factors, Hypoxia-inducible factor, Vadadustat, Procollagen-proline dioxygenase, European Renal Association – European Dialysis and Transplant Association, Hydroxylation, Hypoxia in fish, Ethylenediaminetetraacetic acid

For more information on ERA-EDTA Virtual Congress 2021, visit: https://www.era-edta.org/en/virtualcongress2021/ .

Key Points: 
  • For more information on ERA-EDTA Virtual Congress 2021, visit: https://www.era-edta.org/en/virtualcongress2021/ .
  • Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease.
  • For more information, please visit our website at www.akebia.com , which does not form a part of this release.
  • Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor designed to mimic the physiologic effect of altitude on oxygen availability.

Aptose to Hold Corporate Update Friday, June 11th

Retrieved on: 
星期四, 五月 27, 2021
Enzymes, Branches of biology, Tyrosine kinases, CD135, Acute myeloid leukemia, Cell signaling, Myelodysplastic syndrome, Bruton's tyrosine kinase, Protein kinase inhibitors, Antibody-drug conjugates, Midostaurin, Devimistat

SAN DIEGO and TORONTO, May 27, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Aptose) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that the company management team will provide a corporate update for the investment community on Friday, June 11th, at 8:00 AM ET, in conjunction with participation at the EHA2021 Virtual Congress.

Key Points: 
  • SAN DIEGO and TORONTO, May 27, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Aptose) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that the company management team will provide a corporate update for the investment community on Friday, June 11th, at 8:00 AM ET, in conjunction with participation at the EHA2021 Virtual Congress.
  • The event will include an up-to-date review of clinical data available for Aptoses clinical programs: luxeptinib (CG-806), Aptoses oral, first-in-class FLT3 and BTK kinase inhibitor in two Phase 1 a/b trials, one in patients with relapsed or refractory acute myeloid leukemia (AML) and another in patients with relapsed or refractory B cell malignancies; and APTO-253, a first-in-class small molecule MYC repressor in a Phase 1 a/b trial in patients with relapsed or refractory AML or high risk myelodysplastic syndromes (MDS).

Kronos Bio Announces Participation in Upcoming Investor Conferences

Retrieved on: 
星期三, 五月 26, 2021
Enzymes, Tyrosine kinase inhibitors, Chemical compounds, Entospletinib, Indazoles, Morpholines, Tyrosine kinase receptors, Tyrosine kinases, Branches of biology, CD135, Tyrosine-protein kinase SYK, Acute myeloid leukemia

The fireside chats will be webcast live from the Investors & Media section of the companys website at www.kronosbio.com .

Key Points: 
  • The fireside chats will be webcast live from the Investors & Media section of the companys website at www.kronosbio.com .
  • Kronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that seek to transform the lives of those affected by cancer.
  • Kronos Bio is developing a portfolio of spleen tyrosine kinase (SYK) inhibitors, entospletinib (ENTO) and lanraplenib (LANRA), for the treatment of NPM1-mutated and FLT3-mutated acute myeloid leukemia (AML).
  • Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass.

The Science Behind the Shot: Biotech Tools Developed at Brookhaven Lab Fundamental to Making COVID-19 Vaccines

Retrieved on: 
星期二, 五月 25, 2021
Nucleic acids, Branches of biology, RNA, Enzymes, Biology, Molecular biology, Biotechnology, RNA polymerase, Virus, T7, Polymerase

T7 is a virus that infects E. coli bacteria and commandeers those cells to make copies of the virus.

Key Points: 
  • T7 is a virus that infects E. coli bacteria and commandeers those cells to make copies of the virus.
  • Shortly thereafter, Studier and his team found a way to direct T7s prolific copying capability toward making things other than more T7s.
  • I had wondered casually if T7 RNA polymerase might be involved in making the RNA vaccines, mused Studier, now a senior biophysicist Emeritus.
  • Brookhaven National Laboratory is supported by the U.S. Department of Energys Office of Science.

Corteva Agriscience and Bejo Sign Agreement on Genome Editing

Retrieved on: 
星期一, 五月 17, 2021
Branches of biology, Biology, Life sciences, Genetic engineering, Genome editing, Biotechnology, Immune system, Enzymes, CRISPR, Cas9, Broad Institute

b'WILMINGTON, Del., May 17, 2021 /PRNewswire-PRWeb/ -- Dutch vegetable seed breeder Bejo has entered into a non-exclusive research and commercial license agreement with global agriculture company Corteva Agriscience and the Broad Institute of MIT and Harvard, a U.S.-based biomedical and genomic research center.\nThrough the agreement, Bejo will access CRISPR-Cas9 intellectual property for genome editing for agricultural use, allowing research work and programs as well as potential future commercial applications.

Key Points: 
  • b'WILMINGTON, Del., May 17, 2021 /PRNewswire-PRWeb/ -- Dutch vegetable seed breeder Bejo has entered into a non-exclusive research and commercial license agreement with global agriculture company Corteva Agriscience and the Broad Institute of MIT and Harvard, a U.S.-based biomedical and genomic research center.\nThrough the agreement, Bejo will access CRISPR-Cas9 intellectual property for genome editing for agricultural use, allowing research work and programs as well as potential future commercial applications.
  • For the time being, however, following the development in legislation Bejo will use CRISPR-Cas9-technology for research purpose only.\nBert Schrijver, Director, Research & Development of Bejo said, "Gene editing technologies like CRISPR-Cas9 bring opportunities for accelerating Bejo\'s vegetable breeding programs.
  • They increase our understanding of genetics and provide tools to develop new traits such as abiotic stress and disease resistance.
  • Corteva Agriscience became an independent public company on June 1, 2019, and was previously the Agriculture Division of DowDuPont.

Angion Provides Corporate Update and Reports First Quarter 2021 Financial Results

Retrieved on: 
星期一, 五月 17, 2021
Enzymes, Aldosterone synthase, ROCK2, Forward-looking statement, Kinase, Tyrosine kinase, Enzyme inhibitors

Angion is also currently evaluating ANG-3070, a tyrosine kinase receptor inhibitor for the treatment of fibrotic disease, in Phase 1.

Key Points: 
  • Angion is also currently evaluating ANG-3070, a tyrosine kinase receptor inhibitor for the treatment of fibrotic disease, in Phase 1.
  • Additionally, Angion has preclinical programs for a rho kinase 2 (ROCK2) inhibitor and a CYP11B2 (aldosterone synthase) inhibitor.
  • Such statements are subject to risks and uncertainties and actual results may differ materially from those expressed or implied by such forward-looking statements.
  • Angion undertakes no obligation to update any forward-looking statement in this press release, except as required by law.\nThree Months Ended March 31,\n'

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against FibroGen Inc. (FGEN)

Retrieved on: 
星期五, 五月 14, 2021
Enzymes, Life sciences, Biotechnology, Acetic acids, Isoquinolines, Roxadustat, Hypoxia-inducible factor, Hydroxylation, Procollagen-proline dioxygenase, Biopharmaceutical

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.\nFibroGen is a biopharmaceutical company that develops medicines for the treatment of anemia, fibrotic disease, and cancer.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.\nFibroGen is a biopharmaceutical company that develops medicines for the treatment of anemia, fibrotic disease, and cancer.
  • Its most advanced product is roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor-prolyl hydroxylase (\xe2\x80\x9cHIF-PH\xe2\x80\x9d) activity that acts by stimulating the body\xe2\x80\x99s natural pathway for red cell production.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • If you inquire by email please include your mailing address, telephone number and number of shares purchased.\nThis press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.\nGlancy Prongay & Murray LLP, Los Angeles\n'